Outcomes and predictors of response to fractionated radiotherapy as primary treatment for intracranial meningiomas

Wang, Justin Z; Landry, Alexander P; Nassiri, Farshad; Merali, Zamir A.; Patel, Zeel; Lee, Grace; Rogers, Lauren; Zuccato, Jeffrey; Voisin, Mathew; Muñoz, David G.; Tsang, Derek S.; Laperrière, Normand; Zadeh, Gelareh

doi:10.1016/j.ctro.2023.100631

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, patients undergoing RT after the first surgery presented with a lower number of recurrences suggesting that patients under early adjuvant RT treatment might have prolonged RFS rates and/or time to a second relapse in association with a longer OS. However, these preliminary data are not consistent with previous findings in atypical meningiomas that indicate that early postoperative adjuvant RT has no significant impact on patient OS despite a potential benefit on RFS [48,49], the potential value of RT therapy remaining a matter of debate [44,45,50].…”

Section: Discussioncontrasting

confidence: 92%

Paired Primary and Recurrent Rhabdoid Meningiomas: Cytogenetic Alterations, BAP1 Gene Expression Profile and Patient Outcome

Garrido Ruiz,

Rodriguez,

Corchete

et al. 2024

Biology

View full text Add to dashboard Cite

Rhabdoid meningiomas (RM) are a rare meningioma subtype with a heterogeneous clinical course which is more frequently associated with recurrence, even among tumors undergoing-complete surgical removal. Here, we retrospectively analyzed the clinical-histopathological and cytogenetic features of 29 tumors, from patients with recurrent (seven primary and 14 recurrent tumors) vs. non-recurrent RM (n = 8). Recurrent RM showed one (29%), two (29%) or three (42%) recurrences. BAP1 loss of expression was found in one third of all RM at diagnosis and increased to 100% in subsequent tumor recurrences. Despite both recurrent and non-recurrent RM shared chromosome 22 losses, non-recurrent tumors more frequently displayed extensive losses of chromosome 19p (62%) and/or 19q (50%), together with gains of chromosomes 20 and 21 (38%, respectively), whereas recurrent RM (at diagnosis) displayed more complex genotypic profiles with extensive losses of chromosomes 1p, 14q, 18p, 18q (67% each) and 21p (50%), together with focal gains at chromosome 17q22 (67%). Compared to paired primary tumors, recurrent RM samples revealed additional losses at chromosomes 16q and 19p (50% each), together with gains at chromosomes 1q and 17q in most recurrent tumors (67%, each). All deceased recurrent RM patients corresponded to women with chromosome 17q gains, although no statistical significant differences were found vs. the other RM patients.

show abstract

Section: Discussioncontrasting

confidence: 92%

Paired Primary and Recurrent Rhabdoid Meningiomas: Cytogenetic Alterations, BAP1 Gene Expression Profile and Patient Outcome

Garrido Ruiz,

Rodriguez,

Corchete

et al. 2024

Biology

View full text Add to dashboard Cite

show abstract

Effectiveness and Safety of Hypofractionated Gamma Knife Radiosurgery for Large Meningiomas and Those Adjacent to the Optic Pathway and Brainstem: Preliminary Therapeutic Outcomes

Hirano,

Shinya,

Umekawa

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Recent technologic advancements have facilitated the use of hypofractionated Gamma Knife-based radiosurgery (HF-GKRS) to treat large lesions or those in eloquent areas. This study aimed to analyze the preliminary results of HF-GKRS for these meningiomas, and to determine its effectiveness and safety. Methods This single-center retrospective study analyzed data of patients who underwent HF-GKRS for large meningiomas or those in eloquent areas with > 6 months of follow-up. The primary outcome was progression-free survival (PFS). The secondary outcomes were neurological deterioration, post-treatment T2 signal changes following HF-GKRS, and tumor volume changes. Volumetric analysis of the tumors after treatment was also performed to assess changes in tumor size after HF-GKRS. Results Overall, 24 patients with a median follow-up period of 22 months (range: 6–49 months) were included. Among them, 18 (75%) patients had tumors in close proximity to the optic pathway, and 15 (63%) patients had large lesions (> 10 cm3). The cumulative 1- and 3-year PFS rates were 100% and 92%, respectively. The cumulative 3-year rate of adverse radiation effects was 9%. Overall, 12 patients (50%) showed tumor reduction, with a median tumor reduction rate of 45% (range: 25–58%). Conclusions Our preliminary results revealed that HF-GKRS for large meningiomas or those in eloquent areas is safe and effective, with satisfactory short- and mid-term PFS and low adverse radiation effects. Further research with more patients and longer follow-up periods is required.

show abstract

Outcomes and predictors of response to fractionated radiotherapy as primary treatment for intracranial meningiomas

Cited by 2 publications

References 38 publications

Paired Primary and Recurrent Rhabdoid Meningiomas: Cytogenetic Alterations, BAP1 Gene Expression Profile and Patient Outcome

Paired Primary and Recurrent Rhabdoid Meningiomas: Cytogenetic Alterations, BAP1 Gene Expression Profile and Patient Outcome

Effectiveness and Safety of Hypofractionated Gamma Knife Radiosurgery for Large Meningiomas and Those Adjacent to the Optic Pathway and Brainstem: Preliminary Therapeutic Outcomes

Contact Info

Product

Resources

About